Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A new triple-receptor drug is turning heads in osteoarthritis care. Retatrutide — which targets GLP-1, GIP, and glucagon receptors — slashed knee osteoarthritis pain scores and helped patients lose over 25% of their body weight in phase 3 trials, outperforming placebo and existing GLP-1 drugs like semaglutide. The findings, published in the NEJM, could reshape how obesity-related OA is treated.
A new obesity drug is proving it can do double duty. Retatrutide, a triple-receptor agonist targeting GLP-1, GIP, and glucagon pathways, significantly reduced knee osteoarthritis (OA) pain and body weight in two major phase 3 trials — TRIUMPH-1 and TRIUMPH-4 — with results published simultaneously in the New England Journal of Medicine.
In TRIUMPH-4 (445 patients with obesity and knee OA), retatrutide reduced WOMAC pain scores by over 4.4 points versus 2.43 points with placebo over 68 weeks. Patients lost more than 25% of their body weight — surpassing what's typically seen with single-action GLP-1 drugs like semaglutide or tirzepatide. The larger TRIUMPH-1 trial (2,339 patients) confirmed these findings, with pain reductions of up to 61.6% and weight loss of up to 25% at 80 weeks.
By the Numbers:
Why it matters: With the ACR recently updating its OA guidelines to place greater emphasis on weight loss, retatrutide's dual impact on pain and metabolic health could position it as a significant option for the millions of patients living with obesity-related knee OA — pending FDA approval.
